Genome Liberty

Genome Liberty was a U.S. direct-to-consumer pharmacogenomics startup founded in 2013 by Jeffrey Rosenfeld and Christopher Mason. The company aimed to provide low-cost saliva-based genetic testing focused on actionable gene-drug interactions, helping consumers understand which medications and doses might be safer or more effective based on their DNA. Public descriptions of its offering emphasized pharmacogenomic markers such as rapid codeine metabolism via Cytochrome P450 2D6 and Factor V Leiden risk relevant to estrogen exposure. Available evidence indicates the company was an early personalized-medicine venture rather than a therapeutic drug developer, and it is no longer operating. The business appears to have been affected by the broader FDA crackdown on direct-to-consumer genetic testing during that period.